Form 4: C4 Therapeutics Director Acquires Stock Options

C4 Therapeutics Director Kenneth Carl Anderson acquired 62,000 stock options with an exercise price of $4.25, vesting on June 24, 2027, or the next annual meeting.

Summary

• Kenneth Carl Anderson, a Director at C4 Therapeutics, Inc., acquired 62,000 stock options on June 24, 2026.
• The options have an exercise price of $4.25 per share.
• These options are set to vest in full on June 24, 2027, or at the next annual meeting of the Issuer's stockholders, provided Mr. Anderson remains on the Board.
• The underlying securities are 62,000 shares of Common Stock.
• This transaction is reported under a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard equity grant to a director rather than a significant operational or financial development.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition is part of a pre-established plan, suggesting a structured approach to equity compensation.

Negatives

• The filing only details the acquisition of options, not the company's overall financial performance or operational updates.

Risks

• The vesting schedule for the options is contingent on continued service as a Board member, introducing a risk of forfeiture if service ceases before the vesting date.
• The value of the options is directly tied to the future stock price performance of C4 Therapeutics, which is subject to market volatility and company-specific risks.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the director's continued service, with vesting scheduled for June 24, 2027, or the next annual meeting.

Industry Context

StockSavvy.ai notes that insider option grants, especially to directors, are common in the biotechnology and pharmaceutical sectors as a means of aligning executive interests with shareholder value and incentivizing long-term performance.

Related Party Transactions

• The acquisition of stock options by Director Kenneth Carl Anderson is a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options to a director is a standard compensation practice that aligns director interests with shareholder value. The exercise price and vesting schedule are key terms to monitor.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation strategy for its board members.
• Management: The transaction is part of the executive compensation framework for board members.

Next Steps

• The stock options will vest on June 24, 2027, or the next annual meeting, subject to continued service.
• The director may exercise the vested options at the price of $4.25 per share until the expiration date of June 23, 2036.

Key Dates

Keywords

C4 Therapeutics, Form 4, Stock Options, Insider Trading, Director, Equity Compensation, Securities Exchange Act, Rule 10b5-1